{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper discusses the role of αSyn in Parkinson disease (PD), including its involvement in the formation of Lewy bodies and the production of cytotoxic oligomeric species.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay being described for the variant."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses a combination of 20S proteasome degradation assays, liposome binding assays, and oligomer formation assays to evaluate the effects of the A30P mutation on αSyn behavior.",
          "judgment": "Yes",
          "reasoning": "The general class of assay used effectively models the disease pathogenesis/mechanism defined in Step 1.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper describes the use of controls and replicates in the assays, including wild-type αSyn and other mutant forms as controls.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were included in the assays.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study includes known pathogenic variants (E46K, A53T) and wild-type αSyn as controls.",
          "judgment": "Yes",
          "reasoning": "Variant controls were used in the assay.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The paper does not provide specific statistical analyses or OddsPath calculations for the A30P variant.",
          "judgment": "No",
          "reasoning": "Statistical analyses sufficient to estimate or calculate OddsPath for the functional data are not provided.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study uses a limited number of variant controls (wild-type, E46K, A53T).",
          "judgment": "Yes",
          "reasoning": "The total number of benign/pathogenic variant controls used across the entire study is 10 or less.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A30P variant in SNCA was assessed for its role in PD pathogenesis through functional assays. The evidence supports a pathogenic role, but the strength is limited to supporting due to the lack of extensive statistical analyses and a limited number of variant controls."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "E",
          "alt": "K",
          "position": "46"
        },
        "variant_string_id": "SNCA E46K"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper discusses the role of αSyn in Parkinson disease (PD), including its involvement in the formation of Lewy bodies and the production of cytotoxic oligomeric species.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay being described for the variant."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses a combination of 20S proteasome degradation assays, liposome binding assays, and oligomer formation assays to evaluate the effects of the E46K mutation on αSyn behavior.",
          "judgment": "Yes",
          "reasoning": "The general class of assay used effectively models the disease pathogenesis/mechanism defined in Step 1.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper describes the use of controls and replicates in the assays, including wild-type αSyn and other mutant forms as controls.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were included in the assays.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study includes known pathogenic variants (A30P, A53T) and wild-type αSyn as controls.",
          "judgment": "Yes",
          "reasoning": "Variant controls were used in the assay.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The paper does not provide specific statistical analyses or OddsPath calculations for the E46K variant.",
          "judgment": "No",
          "reasoning": "Statistical analyses sufficient to estimate or calculate OddsPath for the functional data are not provided.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study uses a limited number of variant controls (wild-type, A30P, A53T).",
          "judgment": "Yes",
          "reasoning": "The total number of benign/pathogenic variant controls used across the entire study is 10 or less.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The E46K variant in SNCA was assessed for its role in PD pathogenesis through functional assays. The evidence supports a pathogenic role, but the strength is limited to supporting due to the lack of extensive statistical analyses and a limited number of variant controls."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper discusses the role of αSyn in Parkinson disease (PD), including its involvement in the formation of Lewy bodies and the production of cytotoxic oligomeric species.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay being described for the variant."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses a combination of 20S proteasome degradation assays, liposome binding assays, and oligomer formation assays to evaluate the effects of the A53T mutation on αSyn behavior.",
          "judgment": "Yes",
          "reasoning": "The general class of assay used effectively models the disease pathogenesis/mechanism defined in Step 1.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper describes the use of controls and replicates in the assays, including wild-type αSyn and other mutant forms as controls.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were included in the assays.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study includes known pathogenic variants (A30P, E46K) and wild-type αSyn as controls.",
          "judgment": "Yes",
          "reasoning": "Variant controls were used in the assay.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The paper does not provide specific statistical analyses or OddsPath calculations for the A53T variant.",
          "judgment": "No",
          "reasoning": "Statistical analyses sufficient to estimate or calculate OddsPath for the functional data are not provided.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study uses a limited number of variant controls (wild-type, A30P, E46K).",
          "judgment": "Yes",
          "reasoning": "The total number of benign/pathogenic variant controls used across the entire study is 10 or less.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A53T variant in SNCA was assessed for its role in PD pathogenesis through functional assays. The evidence supports a pathogenic role, but the strength is limited to supporting due to the lack of extensive statistical analyses and a limited number of variant controls."
    }
  ]
}